Maniruzzaman Md, Bhuiyan Md Rokibul Hasan, Jaman Md Sadikuj, Haque Md Shajedul
Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Department of Pharmacy, School of Science & Technology, Varendra University, Rajshahi, 6204, Bangladesh.
Breast Cancer Res Treat. 2025 Feb;209(3):467-485. doi: 10.1007/s10549-024-07600-7. Epub 2025 Jan 10.
Globally, Breast Cancer (BC) is the most frequent cancer in women and has a major negative impact on the physical and emotional well-being of its patients as well as one of the most common cancers to be diagnosed. Numerous studies have been published to identify various molecular pathways, including PI3K/AKT/PTEN. Moreover, growing evidence suggests that miRNAs have been found to play a vital role in the growth and carcinogenesis of tumors. Because of their crucial in the development and course of the illness, all other molecular variables, molecular pathways and microRNAs have gained recognition as important therapeutic targets in BC due to growing interest among researchers in utilizing synthetic drugs and natural products to target these signaling pathway with encouraging outcomes in vivo, in vitro and preclinical trials in recent years.
We searched PUBMED, Science Direct, google scholar, Embase and Scopus for article published from the inception of each database to May 30, 2024.
We discussed PI3K/PTEN/AKT signaling pathway and microRNA activities with breast cancer cell line. In addition, this review covered a wide range of potential drug and natural products as targeted therapies that are linked to downregulating ER-α expression and activity, inhibiting proliferation, migration, metastasis and angiogenesis, inducing apoptosis, cell cycle arrest and sensitizing breast cancer cells. Many studies have been conducted, but as of right now, there are not enough articles to fully explain the treatment and research of breast cancer.
We also need more and more studies on breast cancer from a variety of perspectives. Future scientist will find it easier to consider breast cancer treatment after reading this article presentation. So, the review focuses on our understanding of the roles that microRNA and PI3/PTEN/AKT signaling pathways play in regulating BC. Furthermore, we emphasized the potential therapeutic benefits of newly discovered inhibitors and the use of natural compounds in alone or combinations during preclinical trials.
在全球范围内，乳腺癌（BC）是女性中最常见的癌症，对患者的身心健康有重大负面影响，也是最常被诊断出的癌症之一。已经发表了许多研究来确定各种分子途径，包括PI3K/AKT/PTEN。此外，越来越多的证据表明，已发现miRNA在肿瘤的生长和致癌过程中发挥着至关重要的作用。由于它们在疾病的发展和进程中至关重要，近年来，随着研究人员越来越有兴趣利用合成药物和天然产物靶向这些信号通路，并在体内、体外和临床前试验中取得了令人鼓舞的结果，所有其他分子变量、分子途径和微小RNA已被公认为是乳腺癌重要的治疗靶点。
我们在PUBMED、Science Direct、谷歌学术、Embase和Scopus上搜索了从每个数据库创建到2024年5月30日发表的文章。
我们讨论了PI3K/PTEN/AKT信号通路和微小RNA在乳腺癌细胞系中的活性。此外，本综述涵盖了广泛的潜在药物和天然产物作为靶向治疗，这些治疗与下调雌激素受体-α（ER-α）的表达和活性、抑制增殖、迁移、转移和血管生成、诱导凋亡、细胞周期停滞以及使乳腺癌细胞敏感有关。已经进行了许多研究，但截至目前，没有足够的文章来充分解释乳腺癌的治疗和研究。
我们还需要从各种角度对乳腺癌进行越来越多的研究。未来的科学家在阅读本文介绍后会更容易考虑乳腺癌的治疗。因此，本综述重点阐述了我们对微小RNA和PI3/PTEN/AKT信号通路在调节乳腺癌中所起作用的理解。此外，我们强调了新发现的抑制剂的潜在治疗益处以及天然化合物在临床前试验中单独或联合使用的情况。
